Myung In Pharmaceutical LTD. (KRX:317450)

South Korea · Delayed Price · Currency is KRW

43,300

+3,500 (8.79%)

At close: Jun 29, 2026

-63.86% (1Y)

Market Cap	606.63B
Revenue (ttm)	289.14B +5.5%
Net Income	85.53B +18.6%
EPS	6,593.28 +2.4%
Shares Out	14.60M
PE Ratio	6.30
Forward PE	n/a
Dividend	1,500.00 (3.46%)
Ex-Dividend Date	Dec 29, 2025

Volume	22,568
Open	39,250
Previous Close	39,800
Day's Range	39,250 - 43,450
52-Week Range	39,100 - 134,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 14, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1985

Employees 335

Stock Exchange Korea Stock Exchange

Ticker Symbol 317450

Full Company Profile

Financial Performance

In 2025, KRX:317450's revenue was 287.25 billion, an increase of 6.61% compared to the previous year's 269.43 billion. Earnings were 81.44 billion, an increase of 18.59%.

Financial Statements